{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:48Z","timestamp":1785886788514,"version":"3.56.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"British Rheumatoid Interstitial Lung"},{"name":"Network for the British Society for Rheumatology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study explores whether the prognosis of interstitial lung disease in rheumatoid arthritis (RA-ILD) has improved over time and assesses the potential influence of drug therapy in a large multicentre UK network.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed data from 18 UK centres on patients meeting criteria for both RA and ILD diagnosed over a 25-year period. Data included age, disease duration, outcome and cause of death. We compared all cause and respiratory mortality between RA controls and RA-ILD patients, assessing the influence of specific drugs on mortality in four quartiles based on year of diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 290 RA-ILD patients were identified. All cause (respiratory) mortality was increased at 30% (18%) compared with controls 21% (7%) (P\u00a0=0.02). Overall, prognosis improved over quartiles with median age at death rising from 63\u2009years to 78\u2009years (P\u00a0=0.01). No effect on mortality was detected as a result of DMARD use in RA-ILD. Relative risk (RR) of death from any cause was increased among patients who had received anti-TNF therapy [2.09 (1.1\u20134.0)] P\u00a0=0.03, while RR was lower in those treated with rituximab [0.52(0.1\u20132.1)] or mycophenolate [0.65 (0.2\u20132.0)]. Patients receiving rituximab as their first biologic had longer three (92%), five (82%) and seven year (80%) survival than those whose first biologic was an anti-TNF agent (82%, 76% and 64%, respectively) (P\u00a0=0.037).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This large retrospective multicentre study demonstrates survival of patients with RA-ILD has improved. This may relate to the increasing use of specific immunosuppressive and biologic agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa577","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T19:30:23Z","timestamp":1597433423000},"page":"1882-1890","source":"Crossref","is-referenced-by-count":84,"title":["Rheumatoid arthritis related interstitial lung disease \u2013 improving outcomes over 25 years: a large multicentre UK study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-7908","authenticated-orcid":false,"given":"Clive A","family":"Kelly","sequence":"first","affiliation":[{"name":"Department of Cellular Medicine, University of Newcastle upon Tyne, Gateshead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nisar","sequence":"additional","affiliation":[{"name":"Rheumatology, Burton Hospitals NHS Foundation Trust, Burton on Trent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suba","family":"Arthanari","sequence":"additional","affiliation":[{"name":"Rheumatology, Burton Hospitals NHS Foundation Trust, Burton on Trent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Carty","sequence":"additional","affiliation":[{"name":"Rheumatology, Great Western Hospital NHS Foundation Trust, Swindon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix A","family":"Woodhead","sequence":"additional","affiliation":[{"name":"Chest Medicine, University Hospital Leicester NHS Foundation Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Price-Forbes","sequence":"additional","affiliation":[{"name":"Chest Medicine, University Hospital Leicester NHS Foundation Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Middleton","sequence":"additional","affiliation":[{"name":"Chest Medicine, University of Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Dempsey","sequence":"additional","affiliation":[{"name":"Chest Medicine, University of Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Miller","sequence":"additional","affiliation":[{"name":"Chest Medicine, University of Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Basu","sequence":"additional","affiliation":[{"name":"Rheumatology, Royal Hospital, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dawson","sequence":"additional","affiliation":[{"name":"Rheumatology, St Helens and Knowsley Teaching Hospitals NHS Trust, Knowsley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nav","family":"Sathi","sequence":"additional","affiliation":[{"name":"Rheumatology, St Helens and Knowsley Teaching Hospitals NHS Trust, Knowsley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Rheumatology, North Wales Hospitals Trust, Betsy-Coed, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Palmer","sequence":"additional","affiliation":[{"name":"Medicine, Northern Deanery, Health Education North East, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Medicine, Northern Deanery, Health Education North East, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Janakiraman","sequence":"additional","affiliation":[{"name":"Rheumatology, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouri","family":"Koduri","sequence":"additional","affiliation":[{"name":"Rheumatology, Southend Hospital, Westcliff-on-Sea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Young","sequence":"additional","affiliation":[{"name":"Rheumatology, St Albans City Hospital, St Albans, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2021040620371810600_keaa577-B1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/rheumatology\/33.2.118","article-title":"High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease","volume":"33","author":"McDonagh","year":"1994","journal-title":"Br J Rheumatol"},{"key":"2021040620371810600_keaa577-B3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2021040620371810600_keaa577-B4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021040620371810600_keaa577-B5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kel253","article-title":"Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis","volume":"46","author":"Young","year":"2006","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort study","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021040620371810600_keaa577-B8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/rheumatology\/40.9.1022","article-title":"Interstitial lung disease in patients with rheumatoid arthritis; a comparison with cryptogenic fibrosing alveolitis","volume":"40","author":"Rajasekaran","year":"2001","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"Eur Respir J"},{"key":"2021040620371810600_keaa577-B10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/rheumatology\/keq426","article-title":"Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease","volume":"50","author":"Sathi","year":"2011","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1164\/ajrccm\/144.2.291","article-title":"Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial","volume":"144","author":"Raghu","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2021040620371810600_keaa577-B12","first-page":"51","article-title":"Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis","volume":"7","author":"Howes","year":"1999","journal-title":"Intern Med"},{"key":"2021040620371810600_keaa577-B13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"2021040620371810600_keaa577-B14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","article-title":"Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug","volume":"168","author":"Saketkoo","year":"2008","journal-title":"Arch Intern Med"},{"key":"2021040620371810600_keaa577-B15","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1517\/14656560802591430","article-title":"Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease","volume":"9","author":"Kelly","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"2021040620371810600_keaa577-B16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjmed.2010.11.028","article-title":"Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases","volume":"124","author":"Ramos-Casals","year":"2011","journal-title":"Am J Med"},{"key":"2021040620371810600_keaa577-B17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021040620371810600_keaa577-B18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis\u2013related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Yusof","year":"2017","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00296-012-2587-x","article-title":"Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience","volume":"33","author":"Braun-Moscovici","year":"2013","journal-title":"Rheumatol Int"},{"key":"2021040620371810600_keaa577-B20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021040620371810600_keaa577-B21","first-page":"S301-2(769)","article-title":"Lung abnormalities in subjects with elevations of Rheumatoid Arthritis-related autoantibodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis","volume":"63","author":"Demoruelle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021040620371810600_keaa577-B22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10067-009-1128-9","article-title":"Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA","volume":"28","author":"Gizinski","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2021040620371810600_keaa577-B23","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.rmed.2012.03.006","article-title":"Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease","volume":"106","author":"Fischer","year":"2012","journal-title":"Respir Med"},{"key":"2021040620371810600_keaa577-B24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/rheumatology\/kei240","article-title":"The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis","volume":"45","author":"Manfredsdottir","year":"2006","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/ard.2007.075192","article-title":"Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells","volume":"67","author":"Makrygiannakis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021040620371810600_keaa577-B26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/rheumatology\/keq233","article-title":"The impact of rheumatological evaluation in the management of patients with interstitial lung disease","volume":"50","author":"Castelino","year":"2011","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/BOR.0b013e3282f798ed","article-title":"Lung disease in rheumatoid arthritis","volume":"20","author":"Nannini","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"2021040620371810600_keaa577-B28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/1479972310393758","article-title":"Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?","volume":"8","author":"De Lauretis","year":"2011","journal-title":"Chron Respir Dis"},{"key":"2021040620371810600_keaa577-B29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.31138\/mjr.30.3.147","article-title":"Lung disease in rheumatic disorders","volume":"30","author":"Kelly","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"2021040620371810600_keaa577-B30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2021040620371810600_keaa577-B31","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2021040620371810600_keaa577-B32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis\u2013associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheum"},{"key":"2021040620371810600_keaa577-B33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X15612250","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review","volume":"7","author":"Iqbal","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021040620371810600_keaa577-B34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fmed.2019.00041","article-title":"Biologic treatments in interstitial lung diseases","volume":"6","author":"Karampitsakos","year":"2019","journal-title":"Front Med"},{"key":"2021040620371810600_keaa577-B35","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"Sim\u00e9on-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2021040620371810600_keaa577-B36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2019.00238","article-title":"Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front Med"},{"key":"2021040620371810600_keaa577-B37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2021040620371810600_keaa577-B38","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases\u2013a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B39","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"2021040620371810600_keaa577-B40","doi-asserted-by":"crossref","first-page":"e000473","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD Open"},{"key":"2021040620371810600_keaa577-B41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pupt.2016.02.002","article-title":"Effect of rituximab on pulmonary function in patients with rheumatoid arthritis","volume":"37","author":"Franzen","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"2021040620371810600_keaa577-B42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"2021040620371810600_keaa577-B43","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"2021040620371810600_keaa577-B44","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B45","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/rheumatology\/kex298","article-title":"Comment on: patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Kelly","year":"2017","journal-title":"Rheumatology"},{"key":"2021040620371810600_keaa577-B46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Resp Invest"},{"key":"2021040620371810600_keaa577-B47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/03009742.2011.599072","article-title":"Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade","volume":"40","author":"Mohr","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2021040620371810600_keaa577-B48","first-page":"342","article-title":"Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series","volume":"36","author":"Manfredi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021040620371810600_keaa577-B49","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1882\/36912647\/keaa577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1882\/36912647\/keaa577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T23:40:13Z","timestamp":1617752413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/4\/1882\/5956229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa577","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,11,4]]}}}